Reports Q4 revenue $3.03B, consensus $3.02B. “We made significant progress on our strategy in 2023 and delivered strong results,” said Adam Schechter, chairman and CEO. “Our teams developed and brought important diagnostic testing advancements to market and supported our biopharma clients as they advanced their new drug pipelines and treatments. With the successful integration of several hospital partnerships including Ascension, and the spin of Fortrea, we enter 2024 with a strong foundation and momentum. We remain focused on advancing science, technology and innovation to fuel our growth and fulfill our mission to improve health and improve lives.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on LH:
- Labcorp Announces 2023 Fourth Quarter and Full Year Results
- Laboratory Corporation Of America (LH) Q4 Earnings Cheat Sheet
- PayPal downgraded, United Airlines upgraded: Wall Street’s top analyst calls
- Labcorp initiated with an In Line at Evercore ISI
- Labcorp elevates employee health benefits with WeightWatchers